Evidence map›Paper›PMID 41870042›Full record

ArticleAntimicrobial agents and chemotherapy2026

Clinical and genomic determinants associated with emergent ceftazidime-avibactam plus aztreonam non-susceptibility in ceftazidime-avibactam resistant

William C Shropshire, Jovan Borjan, Iris Y Fonseca, Kathlyn Pham, Melanie Guerrero, Karl Liboro, Allyson Young, Jovelle K Chung, Chin-Ting Wu, Ambrocio Manzanares and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

William C ShropshireDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-8556-3248
Jovan BorjanDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-6323-6211
Iris Y FonsecaDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, California, USA.
Kathlyn PhamDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, California, USA.
Melanie GuerreroDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, California, USA.
Karl LiboroDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, California, USA.
Allyson YoungDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Jovelle K ChungDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0009-0006-4493-4798
Chin-Ting WuDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0009-0003-1947-381X
Ambrocio ManzanaresDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Micah M BhattiDepartment of Laboratory Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-5857-5825
Nancy N VuongDivision of Pharmacy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Guy HandleyDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-1678-5848
Amy SpalloneDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-7513-6522
Roy F ChemalyDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0002-0277-3088
Ayesha KhanDepartment of Pathology and Laboratory Medicine, School of Medicine, University of California Irvine, Irvine, California, USA.
Samuel ShelburneDepartment of Infectious Diseases, Infection Control, and Employee Health, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.ORCID 0000-0001-9721-263X

Funding

National Institute of Allergy and Infectious Diseases P01AI152999National Institute of Allergy and Infectious Diseases R21AI151536
6 · The paper itself

Abstract

Ceftazidime-avibactam (CZA) has revolutionized care for carbapenem-resistant Enterobacterales infections, yet increasing New Delhi metallo-β-lactamase (NDM) prevalence has driven use of CZA plus aztreonam (ATM/CZA). We performed a comprehensive clinical and genomic analysis of ceftazidime-avibactam-resistant

Indexed as

Anti-Bacterial AgentsAzabicyclo CompoundsAztreonamCeftazidimeEscherichia colibeta-LactamasesDrug CombinationsDrug Resistance, Multiple, BacterialEscherichia coli InfectionsHumansMicrobial Sensitivity TestsPlasmidsThird Generation CephalosporinsAnti-Bacterial Agentsavibactam, ceftazidime drug combinationAzabicyclo CompoundsAztreonambeta-LactamasesCeftazidimeDrug CombinationsThird Generation Cephalosporinsavibactam/aztreonamceftazidime/avibactamceftazidime/avibactam plus aztreonammetallo-beta-lactamasesnovel beta-lactam/beta-lactamase inhibitorsplasmid mediated AmpC genes

Identifiers

PMID41870042
PMCPMC13148019

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.